Fieldpoint Private Securities’s United Therapeutics UTHR Stock Holding History

Fieldpoint Private Securities’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$13K	Sell	55 -135	-71%	-$27.4K	﹤0.01%	693
2022 Q1	$34K	Sell	190 -15	-7%	-$2.86K	0.01%	691
2021 Q4	$44K	Buy	205 +20	+11%	+$3.93K	0.01%	650
2021 Q3	$34K	Buy	185 +5	+3%	+$985	0.01%	674
2021 Q2	$37K	Buy	180 +10	+6%	+$1.91K	0.01%	645
2021 Q1	$28K	Buy	170 +10	+6%	+$1.67K	0.01%	706
2020 Q4	$24K	Buy	+160	New	+$21K	0.01%	644

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fieldpoint Private Securities's UTHR Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its United Therapeutics (UTHR) stake by 71% in Q2 2022, selling an estimated $27.4K and leaving 55 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Fieldpoint Private Securities first reported a position in UTHR in Q4 2020 and has held it in 7 quarters since. The position peaked at $44K in Q4 2021. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

Fieldpoint Private Securities held 55 shares of United Therapeutics worth $13K as of Q2 2022.
Fieldpoint Private Securities sold 135 United Therapeutics shares in Q2 2022, an estimated $27.4K.
United Therapeutics made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #693 holding.
Fieldpoint Private Securities first reported a position in United Therapeutics in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's United Therapeutics position peaked at $44K in Q4 2021.
473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.